Drugs / HE3-G3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05923177 | Sep 2023 → Sep 2024 | breast cancer | Tomsk National Research Medical Center of the Russian Academy of Sciences | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HE3-G3 | “SPECT Imaging of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Breast Cancer Using Iodine -123-labelled Designed Ankyrin Repeat Proteins HE3-G3 ([123I] I-(HE)3-G3)” NCT05923177 ↗ |
| Modality | Diagnostic / imaging agent | “SPECT Imaging of Human Epidermal Growth Factor Receptor 2 (HER2) Expression” NCT05923177 ↗ |